Cisco Systems Inc vs Cassava Sciences Inc — how do they compare? Cisco Systems Inc trades at $115.9 (market cap $462.82B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Cisco Systems Inc is far larger — about 11746.7× Cassava Sciences Inc's market cap, and Cisco Systems Inc pays a 1.43% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Cassava Sciences Inc for 37 Days on average.
| CSCO | FLNA | |
|---|---|---|
Market Cap | $462.82B | $39.40M |
Volume | 17,198,164 | 759,018 |
Sector | Technology | Health |
52-Week High | $130.00 | $4.64 |
52-Week Low | $67.46 | $0.68 |
Typical Hold Time | 86 Days | 37 Days |
Enterprise Value | $476.44B | -$43.28M |
Dividend Yield | 1.43% | — |
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $114.89, down 2.59% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $1.22 versus $1.17, continuing a trend of earnings outperformance. Technical indicators show a bullish moving average trend while oscillators suggest potential near-term consolidation. Recent news highlights Cisco's AI-driven networking momentum with Splunk integration and partnerships with NVIDIA, supporting multi-year growth prospects in AI infrastructure.
Cisco presents a compelling investment case with robust profitability metrics (64.52% gross margin, 27.32% ROE) and analyst consensus pointing to 13% upside to the $129.77 price target. Key risks include competitive pressure in AI security from Datadog and CrowdStrike, and the stock's elevated valuation multiples (P/E 35.25, P/S 7.39) that require continued execution. The company's strong cash flow generation and dividend payments provide shareholder value support.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →